3Hayes AJ， Li LY，Lippman ME. Science, medicine, and the future. Antvasculartherapy: a new approach to cancer treatment[J]. BMJ, 1999; 318(7187):853～856
4Rowe PM. Starve the tumor, save the patient[J]. Lancet, 1997;349(9045):1058
5Wojtowicz-Praga SM, Dickson RB.Hawins MJ. Matrix metalloproteinase inhibitors[J].Invest New Drugs, 1997;15(1):61～75
6Harris AL. Are angiostatin and endostatin cures for cancer? [J]Lancet, 1998;351(9116):1598～1599
7Konno H, Tanaka T, Matsuda I, et al. Comparison of the inhibitory effect of theangiogenesis inhibitor,TNP-470, and mitomycin C on the growth and liver metastasis ofhuman colon cancer[J]. Int J Cancer, 1995;61(2):268～271
8Sato H, Ishikawa H, Fujimoto M, et al. Angiocytoxic therapy in human non-smallcell lung cancer cell lines-advantage of combined effects of TNP-470 and SN-38[J].Acta Oncol, 1998;37(1):85～90
1Barinaga M. Designing therapies that target tumor blood vessels. Science, 1997, 275:482-484.
2Konno H. Antitumor effect of the angiogenesis inhibitor TNP-470 on human digestive organ malignancy. Cancer Chemother Pharmacol, 1999,43 :$85-89.
3Furukawa T, Kubota T, Watanabe M, et al. A novel "petientlike" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. Cancer Res, 1993, 53..3070-3072.
4Rowe PM. Starve the tumor, save the patient. Lancet, 1997,349:108.
5Gervaz P, Fontolliet C. Therapeutic potential of the antiangiogenesis drugs TNP-470. Int J Exp Path, 1998, 79.. 359-362.
6Konno H, Tanaka T, Matsuda I, et al. Comparison of the inhibitlry effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer. Int J Cancer, 1995, 61:268-271.
7Burris HA Ⅱ, Moore M J, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial.J Clin Oncol, 1997, 15:2403-2413.
